To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 36
Summary
- Conditions
- Healthy Subjects
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: Each subject will be randomized immediately prior to first study treatment administration on Day 1 Period 1 to one of 12 treatment sequences following a 3 × 4 × 4 Williams square design. Moxifloxacin will be open-label on Day 10 in one period.Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Placebo-controlled.Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04281342
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Trials Idorsia Pharmaceuticals Ltd.
Get Well Soon